JP2020138936A - Oral composition - Google Patents
Oral composition Download PDFInfo
- Publication number
- JP2020138936A JP2020138936A JP2019035917A JP2019035917A JP2020138936A JP 2020138936 A JP2020138936 A JP 2020138936A JP 2019035917 A JP2019035917 A JP 2019035917A JP 2019035917 A JP2019035917 A JP 2019035917A JP 2020138936 A JP2020138936 A JP 2020138936A
- Authority
- JP
- Japan
- Prior art keywords
- sweet potato
- present
- powder
- composition
- glp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 91
- 244000017020 Ipomoea batatas Species 0.000 claims abstract description 80
- 235000002678 Ipomoea batatas Nutrition 0.000 claims abstract description 80
- 235000001466 Ribes nigrum Nutrition 0.000 claims abstract description 46
- 240000001890 Ribes hudsonianum Species 0.000 claims abstract description 19
- 235000016954 Ribes hudsonianum Nutrition 0.000 claims abstract description 19
- 241000219094 Vitaceae Species 0.000 claims description 25
- 235000021021 grapes Nutrition 0.000 claims description 25
- 235000009754 Vitis X bourquina Nutrition 0.000 abstract description 12
- 235000012333 Vitis X labruscana Nutrition 0.000 abstract description 12
- 235000014787 Vitis vinifera Nutrition 0.000 abstract description 12
- 240000006365 Vitis vinifera Species 0.000 abstract 1
- 239000000843 powder Substances 0.000 description 59
- 239000008280 blood Substances 0.000 description 50
- 210000004369 blood Anatomy 0.000 description 50
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 46
- 239000008103 glucose Substances 0.000 description 46
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 41
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 41
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 41
- 239000000284 extract Substances 0.000 description 38
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 37
- 230000000694 effects Effects 0.000 description 30
- 241001312569 Ribes nigrum Species 0.000 description 27
- 230000028327 secretion Effects 0.000 description 24
- 239000000047 product Substances 0.000 description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
- 230000001737 promoting effect Effects 0.000 description 22
- 235000013305 food Nutrition 0.000 description 21
- 235000012054 meals Nutrition 0.000 description 20
- 238000012360 testing method Methods 0.000 description 17
- 235000013399 edible fruits Nutrition 0.000 description 16
- 241000219095 Vitis Species 0.000 description 13
- 230000009471 action Effects 0.000 description 12
- 235000013402 health food Nutrition 0.000 description 12
- 238000011282 treatment Methods 0.000 description 12
- 238000002156 mixing Methods 0.000 description 11
- 208000008589 Obesity Diseases 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 235000020824 obesity Nutrition 0.000 description 10
- 206010012601 diabetes mellitus Diseases 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 8
- 235000013361 beverage Nutrition 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- 239000000469 ethanolic extract Substances 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 235000002532 grape seed extract Nutrition 0.000 description 7
- 229940087603 grape seed extract Drugs 0.000 description 7
- 239000003960 organic solvent Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000001717 vitis vinifera seed extract Substances 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- 230000000580 secretagogue effect Effects 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 235000001916 dieting Nutrition 0.000 description 5
- 230000037228 dieting effect Effects 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 229930003231 vitamin Natural products 0.000 description 5
- 235000013343 vitamin Nutrition 0.000 description 5
- 239000011782 vitamin Substances 0.000 description 5
- 229940088594 vitamin Drugs 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 238000004220 aggregation Methods 0.000 description 4
- 230000002776 aggregation Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 4
- 235000013376 functional food Nutrition 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000012046 mixed solvent Substances 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 229940127557 pharmaceutical product Drugs 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 244000281247 Ribes rubrum Species 0.000 description 3
- 235000002355 Ribes spicatum Nutrition 0.000 description 3
- 239000012670 alkaline solution Substances 0.000 description 3
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 235000020971 citrus fruits Nutrition 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 238000010298 pulverizing process Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- JNTMAZFVYNDPLB-PEDHHIEDSA-N (2S,3S)-2-[[[(2S)-1-[(2S,3S)-2-amino-3-methyl-1-oxopentyl]-2-pyrrolidinyl]-oxomethyl]amino]-3-methylpentanoic acid Chemical compound CC[C@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JNTMAZFVYNDPLB-PEDHHIEDSA-N 0.000 description 2
- UBOXGVDOUJQMTN-UHFFFAOYSA-N 1,1,2-trichloroethane Chemical compound ClCC(Cl)Cl UBOXGVDOUJQMTN-UHFFFAOYSA-N 0.000 description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- 108010039627 Aprotinin Proteins 0.000 description 2
- 240000002319 Citrus sinensis Species 0.000 description 2
- 235000005976 Citrus sinensis Nutrition 0.000 description 2
- 241000207782 Convolvulaceae Species 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 235000016911 Ribes sativum Nutrition 0.000 description 2
- 235000016897 Ribes triste Nutrition 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 235000009392 Vitis Nutrition 0.000 description 2
- 229960004405 aprotinin Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 description 2
- 108010054812 diprotin A Proteins 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000003495 polar organic solvent Substances 0.000 description 2
- 210000003240 portal vein Anatomy 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 1
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 1
- BDOYKFSQFYNPKF-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;sodium Chemical compound [Na].[Na].OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O BDOYKFSQFYNPKF-UHFFFAOYSA-N 0.000 description 1
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 1
- IBFXLTFIVWRUQC-OVGYCKTGSA-N 9b,10b-epoxyroridin d Chemical compound C([C@@]12[C@]3(C)[C@H]4C[C@H]1OC1C5OC5(C)CCC13COC(=O)C1O[C@@]1(C)CCOC(\C=C\C=C/C(=O)O4)C(O)C)O2 IBFXLTFIVWRUQC-OVGYCKTGSA-N 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 244000183685 Citrus aurantium Species 0.000 description 1
- 235000007716 Citrus aurantium Nutrition 0.000 description 1
- 241001672694 Citrus reticulata Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241001091440 Grossulariaceae Species 0.000 description 1
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 235000001537 Ribes X gardonianum Nutrition 0.000 description 1
- 235000001535 Ribes X utile Nutrition 0.000 description 1
- 235000002357 Ribes grossularia Nutrition 0.000 description 1
- 244000171263 Ribes grossularia Species 0.000 description 1
- 235000016919 Ribes petraeum Nutrition 0.000 description 1
- 241001093501 Rutaceae Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 241001593968 Vitis palmata Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 230000000225 effect on diabetes Effects 0.000 description 1
- 230000000062 effect on obesity Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000004387 flavanoid group Chemical group 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940025878 hesperidin Drugs 0.000 description 1
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 1
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 235000021581 juice product Nutrition 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- -1 rounds Substances 0.000 description 1
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 235000013570 smoothie Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000013322 soy milk Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
本発明は、甘藷を含有する経口組成物に関する。 The present invention relates to an oral composition containing sweet potato.
近年、健康に対する関心の高まり等を背景に、種々の健康食品の開発が行われており、健康食品に用いられる様々な素材の研究が行われている。 In recent years, various health foods have been developed against the background of growing interest in health, and research on various materials used in health foods has been conducted.
例えば、ヒルガオ科に属する甘藷（さつまいも）の茎葉は、食料の豊富な現代においては、ほとんど食されておらず、その有効活用が求められている。近年、この甘藷茎葉は、ビタミン、ミネラルなどの健康に有効な成分を含有することが明らかにされ、生活習慣病予防を目的とした食品原料として利用され始めている。 For example, the foliage of sweet potato, which belongs to the Convolvulaceae family, is rarely eaten in modern times when food is abundant, and its effective utilization is required. In recent years, it has been clarified that this sweet potato foliage contains ingredients effective for health such as vitamins and minerals, and it has begun to be used as a food raw material for the purpose of preventing lifestyle-related diseases.
例えば、特許文献１には、甘藷茎葉を水に浸漬、煮沸し、溶出液を濃縮し、得られたエキスを海苔に塗布したカリウム含有食品が記載されている。また、特許文献２には、甘藷茎葉の処理方法として、甘藷茎葉を洗浄する際に、含有されるビタミン、ミネラルなどの有効成分を流出させないように、噴出水で洗浄し、乾燥、粉末化することが記載されている。 For example, Patent Document 1 describes a potassium-containing food in which sweet potato foliage is immersed in water, boiled, the eluate is concentrated, and the obtained extract is applied to seaweed. Further, in Patent Document 2, as a method for treating sweet potato foliage, when the sweet potato foliage is washed, it is washed with spouted water, dried and powdered so as not to let out active ingredients such as vitamins and minerals contained therein. It is stated that.
さらに、甘藷茎葉の茎部は硬い繊維質であるため、粉末化などの製剤化が困難であること、その結果、適用範囲が食品または医薬品の一部に限られるなどの問題点、あるいは甘藷茎葉に含まれる成分が不安定であることなどの問題点がある。そこで、甘藷茎葉を有効に利用するための工夫が種々研究されている。 Furthermore, since the stem of sweet potato foliage is hard fibrous, it is difficult to formulate it by powdering, and as a result, the scope of application is limited to a part of foods or pharmaceuticals, or sweet potato foliage. There are problems such as unstable components contained in. Therefore, various measures for effectively utilizing sweet potato foliage have been studied.
本発明の課題は、有用な機能を有する甘藷茎葉含有経口組成物を提供することにある。 An object of the present invention is to provide an oral composition containing sweet potato foliage having a useful function.
本発明者らは、甘藷茎葉と共にブドウ、カシス及びオレンジから選ばれる少なくとも１種を用いることにより、優れたＧＬＰ−１分泌促進作用が得られることを見いだし、本発明を完成するに至った。また、甘藷茎葉と共にブドウ、柑橘類から選ばれる少なくとも１種を用いることにより、血糖値上昇抑制作用が得られることを見いだし、本発明を完成するに至った。また、甘藷茎葉と共にブドウ、柑橘類から選ばれる少なくとも１種を用いることにより、分散性が向上することを見いだし、本発明を完成するに至った。 The present inventors have found that an excellent GLP-1 secretagogue action can be obtained by using at least one selected from grapes, blackcurrants and oranges together with sweet potato foliage, and have completed the present invention. Further, they have found that the effect of suppressing an increase in blood glucose level can be obtained by using at least one selected from grapes and citrus fruits together with sweet potato foliage, and have completed the present invention. Further, they have found that the dispersibility is improved by using at least one selected from grapes and citrus fruits together with sweet potato foliage, and have completed the present invention.
すなわち、本発明は、以下のとおりのものである。
［１］甘藷茎葉と、ブドウ、カシス及びオレンジから選ばれる少なくとも１種とを含有することを特徴とする経口組成物。
［２］甘藷茎葉と、ブドウ、カシス及びオレンジから選ばれる少なくとも２種とを含有することを特徴とする経口組成物。
［３］甘藷茎葉、ブドウ及びカシスを含有することを特徴とする経口組成物。
［４］甘藷茎葉、ブドウ、カシス及びオレンジを含有することを特徴とする経口組成物。
That is, the present invention is as follows.
[1] An oral composition comprising sweet potato foliage and at least one selected from grapes, blackcurrants and oranges.
[2] An oral composition comprising sweet potato foliage and at least two kinds selected from grapes, blackcurrants and oranges.
[3] An oral composition comprising sweet potato foliage, grapes and blackcurrant.
[4] An oral composition comprising sweet potato foliage, grapes, blackcurrant and orange.
本発明の経口組成物は、優れたＧＬＰ−１分泌促進作用や血糖値上昇抑制作用を有する。また、本発明の経口組成物は、分散性が高く、ダマの形成を抑制することができる。 The oral composition of the present invention has an excellent GLP-1 secretion promoting action and a blood glucose level elevation suppressing action. In addition, the oral composition of the present invention has high dispersibility and can suppress the formation of lumps.
本発明の経口組成物は、甘藷茎葉と、ブドウ、カシス及びオレンジから選ばれる少なくとも１種とを含有することを特徴とする。 The oral composition of the present invention is characterized by containing sweet potato foliage and at least one selected from grapes, blackcurrants and oranges.
本発明の経口組成物は、優れたＧＬＰ−１分泌促進作用を有する。このＧＬＰ−１分泌促進作用を有する本発明の経口組成物は、糖尿病および肥満の予防および改善に有用であり、そして医薬品および飲食品に好適に利用され得る。 The oral composition of the present invention has an excellent GLP-1 secretagogue action. The oral composition of the present invention having a GLP-1 secretagogue action is useful for the prevention and amelioration of diabetes and obesity, and can be suitably used for pharmaceuticals and foods and drinks.
本発明の経口組成物は、優れた血糖値上昇抑制作用を有する。この血糖値上昇抑制作用を有する本発明の経口組成物は、糖尿病および肥満の予防および改善に有用であり、そして医薬品および飲食品に好適に利用され得る。 The oral composition of the present invention has an excellent effect of suppressing an increase in blood glucose level. The oral composition of the present invention having an action of suppressing an increase in blood glucose level is useful for prevention and amelioration of diabetes and obesity, and can be suitably used for pharmaceuticals and foods and drinks.
また、本発明の経口組成物は、甘藷茎葉に比して高い分散性を有する。すなわち、本発明の経口組成物は、紛体（粉末）の場合、凝集しにくい。したがって、水やお湯等の液体に溶かして摂取する場合、溶けやすく、簡単に混合することができる。さらに、本発明の経口組成物の製造工程では、粉末の混合工程において粉末同士の付着を抑制するため、塊（ダマ）の形成を抑制して均一な混合が可能となる。すなわち、本発明の分散性の高い経口組成物は、単に混合するだけで調製できるものであり、その調製も容易である。例えば、凝集性が強く、ダマを形成しやすい原料を混合する際には、その原料について粉砕機を用いた解砕等の前処理を行い、原料の流動性を確保したうえで仕込み、さらに、仕込み後は、再凝集しないようできるだけ速やかに給気し、流動を開始する必要があることが知られているが、本発明の経口組成物はこのような煩雑な操作を行う必要がない。また、凝集性が強く、ダマを形成しやすい原料を混合する際には、その原料に賦形剤を予め混合することで付着性を緩和できる場合があることが知られているが、本発明の経口組成物はこのような賦形剤の添加も必要ない。また、本発明の組成物は分散性が高いため、さらに本発明の成分以外の素材を混合して本発明の経口組成物とする場合にも、上記のような煩雑な操作を行う必要がなく、単に混合するだけで調製することができる。このように、本発明の組成物は分散性が高く、ダマノ形成を抑制できるため、粉体（粉末）の製造工程だけではなく、顆粒、錠剤、カプセルの製造工程においても、作業効率の悪化を減らすことや作業効率をあげることができる。 In addition, the oral composition of the present invention has high dispersibility as compared with sweet potato foliage. That is, the oral composition of the present invention does not easily aggregate in the case of powder. Therefore, when it is dissolved in a liquid such as water or hot water and ingested, it is easily dissolved and can be easily mixed. Further, in the step of producing the oral composition of the present invention, since the adhesion between the powders is suppressed in the powder mixing step, the formation of lumps (lumps) is suppressed and uniform mixing is possible. That is, the highly dispersible oral composition of the present invention can be prepared simply by mixing, and the preparation thereof is also easy. For example, when mixing raw materials that have strong cohesiveness and easily form lumps, the raw materials are pretreated by crushing using a crusher, etc. to ensure the fluidity of the raw materials, and then charged. It is known that after the preparation, it is necessary to supply air as soon as possible so as not to reaggregate and start the flow, but the oral composition of the present invention does not need to perform such a complicated operation. Further, it is known that when a raw material having strong cohesiveness and easily forming lumps is mixed, the adhesiveness may be relaxed by mixing an excipient with the raw material in advance. Oral compositions of the above do not require the addition of such excipients. Further, since the composition of the present invention has high dispersibility, even when materials other than the components of the present invention are mixed to obtain the oral composition of the present invention, it is not necessary to perform the above-mentioned complicated operations. , Can be prepared by simply mixing. As described above, since the composition of the present invention has high dispersibility and can suppress the formation of damano, the work efficiency is deteriorated not only in the manufacturing process of powder (powder) but also in the manufacturing process of granules, tablets and capsules. It can be reduced and work efficiency can be improved.
＜甘藷茎葉＞
甘藷とは、ヒルガオ科に属する植物をいい、一般にサツマイモと呼ばれる。甘藷の品種は、特に限定されない。例えば、すいおう、ジョイホワイト、コガネセンガン、シロユタカ、サツマスターチ、アヤムラサキなどの品種が挙げられる。本明細書において「甘藷茎葉」とは、「甘藷の茎および甘藷の葉の少なくともいずれか」を指し、甘藷の葉のみ、甘藷の茎のみ、および甘藷の茎と葉との両方を含む。葉部と茎部とに篩別したものを用いてもよく、篩別しないものを用いてもよい。本発明では、ＧＬＰ−１分泌促進の効果や血糖値上昇抑制の効果の観点又は分散性の向上の観点から甘藷の茎と葉の両方を含む茎葉が特に好ましい。
<Sweet potato foliage>
Sweet potato refers to a plant belonging to the Convolvulaceae family, and is generally called sweet potato. The variety of sweet potato is not particularly limited. For example, varieties such as Suiou, Joy White, Koganesengan, Shiroyutaka, Satsu Starch, and Ayamurasaki can be mentioned. As used herein, the term "sweet potato stalk and leaf" refers to "at least one of sweet potato stalk and sweet potato leaf" and includes only sweet potato stalk, sweet potato stalk only, and both sweet potato stalk and leaf. Those that have been sieved between the leaves and stems may be used, or those that are not sieved may be used. In the present invention, foliage containing both stalks and leaves of sweet potato is particularly preferable from the viewpoint of the effect of promoting GLP-1 secretion, the effect of suppressing the increase in blood glucose level, or the viewpoint of improving dispersibility.
＜甘藷茎葉加工物＞
甘藷茎葉は、品質安定性、長期保存性などの点から、加工（処理）が施され得る。本明細書において「甘藷茎葉加工物」とは、何らかの加工（処理）が施された甘藷茎葉をいう。処理としては、例えば、加熱処理、乾燥処理、粉末化処理、圧搾処理、抽出処理などが挙げられる。これらの処理は、１種のみを行ってもよく、２種以上を行ってもよい。収穫した甘藷茎葉は、付着した泥などを水で洗浄した後にこれらの処理に供され得る。本発明で使用する甘藷茎葉としては、乾燥させて粉砕し粉末にしたもの（粉砕末）や、水、低級アルコール又はそれらの混合溶媒等で抽出した抽出物（エキス末）、搾汁物又はその乾燥粉末（搾汁粉末）を使用できるが、ＧＬＰ−１分泌促進の効果や血糖値上昇抑制の効果の観点又は分散性の向上の観点から、粉砕末やエキス末を使用することが好ましい。
<Sweet potato foliage processed product>
The sweet potato foliage can be processed (treated) from the viewpoint of quality stability, long-term storage, and the like. As used herein, the term "processed sweet potato foliage" refers to sweet potato foliage that has undergone some processing (treatment). Examples of the treatment include heat treatment, drying treatment, pulverization treatment, pressing treatment, extraction treatment and the like. These treatments may be performed by only one type or two or more types. The harvested sweet potato foliage can be subjected to these treatments after washing the attached mud and the like with water. The sweet potato foliage used in the present invention includes dried and crushed powder (crushed powder), extract extracted with water, lower alcohol or a mixed solvent thereof (extract powder), juice or dried product thereof. Although powder (squeezed powder) can be used, it is preferable to use pulverized powder or extract powder from the viewpoint of the effect of promoting GLP-1 secretion, the effect of suppressing the increase in blood glucose level, or the viewpoint of improving dispersibility.
甘藷茎葉加工物の抽出は、甘藷茎葉の生茎葉または上記の加熱処理、乾燥処理、粉末化処理、圧搾処理などのいずれか少なくとも１つの処理が施された甘藷茎葉を溶媒と接触させることにより行われ得る。抽出用の溶媒としては、水、有機溶媒または含水有機溶媒が挙げられる。有機溶媒としては、例えば、メタノール、エタノール、１−プロパノール、２−プロパノール、１−ブタノール、２−ブタノール、アセトン、ヘキサン、シクロヘキサン、プロピレングリコール、エチルメチルケトン、グリセリン、酢酸メチル、酢酸エチル、ジエチルエーテル、ジクロロメタン、食用油脂、１，１，１，２−テトラフルオロエタン、１，１，２−トリクロロエタンなどが挙げられる。本発明においては、これらの有機溶媒の中でも、アルコール（メタノール、エタノールなど）などの極性有機溶媒が好ましく、エタノールがさらに好ましい。含水有機溶媒としては、好ましくは含水アルコールなどの含水極性有機溶媒、より好ましくは含水エタノールが挙げられる。含水有機溶媒中に含まれる有機溶媒の割合は、特に限定されないが、好ましくは８０容量％未満、より好ましくは７０容量％未満である。含水エタノールの場合、エタノールを８０容量％未満、好ましくは１０容量％〜７０容量％、より好ましくは２０容量％〜６５容量％含有する含水エタノールが用いられ得る。本発明で使用する甘藷茎葉加工物の抽出溶媒としては、ＧＬＰ−１分泌促進の効果や血糖値上昇抑制の効果の観点から、エタノール容量６０％の含水エタノールが好ましい。 Extraction of the processed sweet potato foliage is carried out by contacting the raw foliage of sweet potato foliage or the sweet potato foliage subjected to at least one of the above heat treatment, drying treatment, powdering treatment, squeezing treatment and the like with a solvent. Can be Examples of the solvent for extraction include water, organic solvents and hydrous organic solvents. Examples of the organic solvent include methanol, ethanol, 1-propanol, 2-propanol, 1-butanol, 2-butanol, acetone, hexane, cyclohexane, propylene glycol, ethyl methyl ketone, glycerin, methyl acetate, ethyl acetate and diethyl ether. , Hexane, edible oils and fats, 1,1,1,2-tetrafluoroethane, 1,1,2-trichloroethane and the like. In the present invention, among these organic solvents, polar organic solvents such as alcohol (methanol, ethanol, etc.) are preferable, and ethanol is more preferable. Examples of the hydrous organic solvent include a hydrous polar organic solvent such as a hydrous alcohol, and more preferably a hydrous ethanol. The proportion of the organic solvent contained in the hydrous organic solvent is not particularly limited, but is preferably less than 80% by volume, more preferably less than 70% by volume. In the case of hydrous ethanol, hydrous ethanol containing less than 80% by volume of ethanol, preferably 10% by volume to 70% by volume, more preferably 20% by volume to 65% by volume can be used. As the extraction solvent for the processed sweet potato foliage product used in the present invention, hydrous ethanol having an ethanol volume of 60% is preferable from the viewpoint of the effect of promoting GLP-1 secretion and the effect of suppressing the increase in blood glucose level.
＜ブドウ＞
ブドウは、ブドウ科に属する植物である。本発明で使用するブドウとしては、実、皮、種子、葉などを用いることができ、特に限定するものではないが、実、種子、又は葉が好ましい。また、ブドウとしては、欧米種（学名：Vitis. vinifera）、米国種（学名：Vitis. labrusca）など、特に限定するものではなく、いかなる品種を用いてもよいが、欧米種が好ましい。特に、赤色、紫色、青色、紺色又は黒色に近い果皮と赤色の果肉の欧米種である赤ブドウが好ましい。本発明で使用するブドウは、ブドウを加工した加工物を用いてもよく、例えば、ブドウの乾燥物や、乾燥させて粉砕し粉末にしたもの（粉砕末）や、水、低級アルコール又はそれらの混合溶媒等で抽出した抽出物（エキス末）や、発酵物（発酵粉末）を使用でき、エキス末を使用することが好ましく、エタノールで抽出したエキス末が特に好ましい。本発明で使用するブドウとしては、ＧＬＰ−１分泌促進の効果や血糖値上昇抑制の効果の観点又は分散性の向上の効果の観点から、ブドウの実、種子、又は葉のエキス末が好ましく、特に、ブドウの種子をエタノール抽出したエキス末が好ましい。
<Grape>
Grape is a plant belonging to the family Grapes. As the grape used in the present invention, fruits, skins, seeds, leaves and the like can be used, and although not particularly limited, fruits, seeds or leaves are preferable. The grapes are not particularly limited to Western varieties (scientific name: Vitis. Vinifera), American varieties (scientific name: Vitis. Labrusca), and any varieties may be used, but Western varieties are preferable. In particular, red grapes, which are Western species of red, purple, blue, dark blue or near-black peel and red flesh, are preferable. The grapes used in the present invention may be processed grapes, for example, dried grapes, dried and crushed powder (crushed powder), water, lower alcohol or theirs. An extract (extract powder) extracted with a mixed solvent or the like or a fermented product (fermented powder) can be used, and it is preferable to use the extract powder, and the extract powder extracted with ethanol is particularly preferable. As the grape used in the present invention, the extract powder of grape seeds, seeds, or leaves is preferable from the viewpoint of the effect of promoting GLP-1 secretion, the effect of suppressing the increase in blood glucose level, or the effect of improving dispersibility. In particular, an extract powder obtained by extracting grape seeds with ethanol is preferable.
＜カシス＞
カシスは、スグリ科スグリ属に分類される植物で、その葉は生薬として、果実はゼリーやジャム等として利用されている。本発明で使用するカシスとしては、実、皮、種子、葉などを用いることができ、特に限定するものではないが、実、皮又は種子が好ましく、特に実が好ましい。また、カシスとしては、セイヨウスグリ（グズベリー）、フサスグリ（アカスグリ）、クロスグリ（カシス）など、特に限定するものではなく、いかなる品種を用いてもよいが、クロスグリ（カシス）が好ましい。クロスグリの果実は黒に近い濃紫色をしており、ビタミンＣやアントシアニンを豊富に含んでいる。本発明で使用するカシスは、カシスを加工した加工物を用いてもよく、例えば、カシスの乾燥物や、乾燥させて粉砕し粉末にしたもの（粉砕末）や、水、低級アルコール又はそれらの混合溶媒等で抽出した抽出物（エキス末）、搾汁物又はその乾燥粉末（搾汁末）を使用でき、エキス末を使用することが好ましく、水で抽出したエキス末が特に好ましい。本発明で使用するカシスとしては、ＧＬＰ−１分泌促進の効果や血糖値上昇抑制の効果の観点又は分散性の向上の効果の観点から、カシスの実、皮のエキス末が好ましく、特に、カシスの実、皮を水で抽出したエキス末が好ましい。
<Cassis>
Cassis is a plant classified in the genus Currant of the Grossulariaceae family, and its leaves are used as crude drugs and its fruits are used as jellies and jams. As the cassis used in the present invention, fruits, skins, seeds, leaves and the like can be used, and although not particularly limited, fruits, skins or seeds are preferable, and fruits are particularly preferable. The cassis is not particularly limited, such as gooseberry (guzberry), redcurrant (redcurrant), and blackcurrant (cassis), and any variety may be used, but blackcurrant (cassis) is preferable. The fruits of blackcurrant have a deep purple color close to black and are rich in vitamin C and anthocyanins. As the cassis used in the present invention, a processed product obtained by processing the cassis may be used, for example, a dried product of the cassis, a dried and crushed powder (ground powder), water, a lower alcohol or a product thereof. An extract (extract powder) extracted with a mixed solvent or the like, a juice product or a dry powder thereof (squeezed powder) can be used, and it is preferable to use the extract powder, and the extract powder extracted with water is particularly preferable. As the cassis used in the present invention, the extract powder of cassis fruit and skin is preferable from the viewpoint of the effect of promoting GLP-1 secretion, the effect of suppressing the increase in blood glucose level, or the effect of improving dispersibility, and in particular, cassis. Extract powder obtained by extracting the fruit and skin with water is preferable.
＜オレンジ＞
オレンジは、ミカン科ミカン属に分類される植物である。本発明で使用するオレンジとしては、実、皮、種子、葉などを用いることができ、特にン限定するものではないが、実、皮又は種子が好ましく、特に未が好ましい。また、オレンジとしては、スイートオレンジ、サワーオレンジ、マンダリンオレンジなど、特に限定するものではなく、いかなる品種を用いてもよいが、スイートオレンジが好ましい。本発明で使用するオレンジは、オレンジを加工した加工物を用いてもよく、例えば、オレンジの乾燥物や、乾燥させて粉砕し粉末にしたもの（粉砕末）や、水、低級アルコール又はそれらの混合溶媒等で抽出した抽出物（エキス末）、搾汁物又はその乾燥粉末（搾汁末）を使用でき、エキス末を使用することが好ましく、アルカリ溶液で抽出したエキス末が特に好ましい。本発明で使用するオレンジとしては、ＧＬＰ−１分泌促進の効果や血糖値上昇抑制の効果の観点又は分散性の向上の効果の観点から、オレンジの実、皮のエキス末が好ましく、特に、オレンジの実、皮をアルカリ溶液で抽出したエキス末が好ましい。
<Orange>
Orange is a plant classified in the genus Citrus of the Rutaceae family. As the orange used in the present invention, fruits, skins, seeds, leaves and the like can be used, and although not particularly limited, fruits, skins or seeds are preferable, and seeds are particularly preferable. The orange is not particularly limited, such as sweet orange, sour orange, and mandarin orange, and any variety may be used, but sweet orange is preferable. As the orange used in the present invention, a processed product obtained by processing an orange may be used, for example, a dried orange product, a dried and crushed powder (crushed powder), water, a lower alcohol, or a product thereof. An extract (extract powder) extracted with a mixed solvent or the like, a squeezed product or a dry powder thereof (squeezed powder) can be used, and it is preferable to use the extract powder, and the extract powder extracted with an alkaline solution is particularly preferable. As the orange used in the present invention, the extract powder of orange fruit and skin is preferable from the viewpoint of the effect of promoting GLP-1 secretion, the effect of suppressing the increase in blood glucose level, or the effect of improving dispersibility, and in particular, orange. Extract powder obtained by extracting the fruit and skin with an alkaline solution is preferable.
本発明の経口組成物は、一般的な食品、食品添加剤、飼料等の他、ＧＬＰ−１分泌促進作用又は血糖値上昇抑制作用に基づく糖尿病および肥満の予防および改善効果を有することから、例えば、特定保健用食品、栄養機能食品、機能性表示食品等の所定機関より効能の表示が認められた機能性食品などのいわゆる健康食品や、医薬品（医薬部外品を含む）として用いることができる。 Since the oral composition of the present invention has a preventive and ameliorating effect on diabetes and obesity based on a GLP-1 secretion promoting action or a blood glucose level elevation suppressing action in addition to general foods, food additives, feeds and the like, for example. , Specified health foods, nutritionally functional foods, functional foods, etc. Can be used as so-called health foods such as functional foods whose efficacy has been approved by a prescribed organization, or as pharmaceuticals (including non-pharmaceutical products). ..
すなわち、本発明の経口組成物は、いわゆる健康食品や医薬品等のダイエットのために用いられるダイエット用経口組成物として用いることができ、かかるダイエット用経口組成物としては、甘藷茎葉と、ブドウ、カシス、及びオレンジから選ばれる少なくとも１種を含有を含有し、ＧＬＰ−１分泌促進や血糖値上昇抑制、ダイエットに用いられる点において、製品として他の製品と区別することができるものであれば特に制限されるものではなく、例えば、本発明に係る製品の本体、包装、説明書、宣伝物のいずれかに、ＧＬＰ−１分泌促進や血糖値上昇抑制、糖尿病の予防、糖尿病の改善、肥満の予防、肥満の改善等のダイエットの機能がある旨を表示したものが本発明の範囲に含まれる。なお、本発明の経口組成物は、製品の包装等に、本発明の成分（甘藷茎葉と、ブドウ、カシス、及びオレンジから選ばれる少なくとも１種）がＧＬＰ−１分泌促進や血糖値上昇抑制、ダイエットの有効成分として表示されているものに限られない。例えば、有効成分を特定していないものであってもよく、特定の素材を有効成分として表示したものであってもよい。 That is, the oral composition of the present invention can be used as an oral composition for dieting used for dieting of so-called health foods, pharmaceuticals and the like, and such oral composition for dieting includes sweet potato foliage, grapes and cassis. , And at least one selected from orange, which is particularly limited as long as it can be distinguished from other products in terms of promoting GLP-1 secretion, suppressing increase in blood glucose level, and being used for dieting. For example, in the main body, packaging, instruction manual, or advertisement of the product according to the present invention, GLP-1 secretion is promoted, blood glucose level rise is suppressed, diabetes is prevented, diabetes is improved, and obesity is prevented. The scope of the present invention includes those indicating that they have a dieting function such as improvement of obesity. In the oral composition of the present invention, the components of the present invention (at least one selected from sweet potato foliage, grapes, cassis, and orange) are used in the packaging of the product to promote GLP-1 secretion and suppress the increase in blood glucose level. It is not limited to those listed as active ingredients in the diet. For example, the active ingredient may not be specified, or a specific material may be displayed as the active ingredient.
本発明によれば、甘藷茎葉又は甘藷茎葉加工物を、ＧＬＰ−１分泌促進組成物として使用し得る。ＧＬＰ−１は、食物の刺激による、インスリン分泌促進、満腹中枢の刺激、消化管の蠕動運動抑制などの作用を有する。本発明のＧＬＰ−１分泌促進組成物は、糖尿病および肥満の予防および改善に有用である。本発明のＧＬＰ−１分泌促進組成物は、ＧＬＰ−１分泌の増大によって改善される任意の症状の予防および治療にも有用である。 According to the present invention, a sweet potato foliage or a processed sweet potato foliage can be used as a GLP-1 secretion promoting composition. GLP-1 has actions such as promoting insulin secretion, stimulating the satiety center, and suppressing peristaltic movement of the digestive tract by stimulating food. The GLP-1 secretagogue composition of the present invention is useful for the prevention and amelioration of diabetes and obesity. The GLP-1 secretagogue composition of the present invention is also useful for the prevention and treatment of any symptom ameliorated by increased GLP-1 secretion.
また、本発明のＧＬＰ−１分布付促進組成物としては、甘藷茎葉と、ブドウ、カシス及びオレンジから選ばれる少なくとも１種を含有し、ＧＬＰ−１分泌促進に用いられる点において、製品として他の製品と区別することができるものであれば特に制限されるものではなく、例えば、本発明に係る製品の本体、包装、説明書、宣伝物のいずれかにＧＬＰ−１分泌促進作用の機能がある旨を表示したものが本発明の範囲に含まれる。例えば、医薬品（医薬部外品を含む）や、特定保健用食品、栄養機能食品、機能性表示食品等の所定機関より効能の表示が認められた機能性食品などのいわゆる健康食品や、飼料等を挙げることができる。いわゆる健康食品においては、「ＧＬＰ−１の分泌を促進する」、「糖尿病の予防に」、「肥満の予防に」、「糖尿病の改善に」、「肥満を改善したい方に」等を表示したものを例示することができる。これらの健康食品は、食事と別に摂取してもよいが、食事の際に摂取することが好ましく、例えば、食事前１時間から食事後１時間の間に摂取することが好ましく、食事前０．５時間から食事後０．５時間の間に摂取することがより好ましく、食事前０．５時間から食事開始時まで或いは食事中に摂取することがさらに好ましい。等を表示したものを例示することができる。 Further, the GLP-1 distribution promoting composition of the present invention contains at least one selected from sweet potato foliage and grapes, cassis and orange, and is used as a product for promoting GLP-1 secretion. It is not particularly limited as long as it can be distinguished from the product, and for example, any of the main body, packaging, instruction manual, and advertisement of the product according to the present invention has a function of promoting GLP-1 secretion. The indication to that effect is included in the scope of the present invention. For example, so-called health foods such as pharmaceuticals (including non-pharmaceutical products), foods for specified health use, foods with nutritional function, foods with functional claims, etc. Can be mentioned. In so-called health foods, "promote GLP-1 secretion", "prevention of diabetes", "prevention of obesity", "improvement of diabetes", "for those who want to improve obesity", etc. are displayed. Things can be illustrated. These health foods may be taken separately from meals, but are preferably taken at the time of meals, for example, between 1 hour before meals and 1 hour after meals, 0. It is more preferably taken between 5 hours and 0.5 hours after a meal, and even more preferably from 0.5 hours before a meal to the beginning of a meal or during a meal. Etc. can be illustrated as an example.
本発明によれば、甘藷茎葉又は甘藷茎葉加工物を、血糖値上昇抑制組成物として使用し得る。本発明の血糖値上昇抑制組成物は、食後の血糖値の急激な上昇を抑制することができ、さらに空腹時の血糖値を低下させることも期待できる。また、本発明の血糖値上昇抑制組成物は、経口投与することによっても血糖値上昇抑制作用を示し得ることから、日常的な使用態様で使用することが可能である。 According to the present invention, a sweet potato foliage or a processed sweet potato foliage can be used as a composition for suppressing an increase in blood glucose level. The composition for suppressing an increase in blood glucose level of the present invention can suppress a rapid increase in blood glucose level after meals, and can be expected to further reduce the blood glucose level on an empty stomach. In addition, the composition for suppressing an increase in blood glucose level of the present invention can also exhibit an effect of suppressing an increase in blood glucose level by oral administration, and therefore can be used in daily use modes.
また、本発明の血糖値上昇抑制組成物としては、甘藷茎葉と、ブドウ、カシス及びオレンジから選ばれる少なくとも１種を含有し、血糖値上昇抑制に用いられる点において、製品として他の製品と区別することができるものであれば特に制限されるものではなく、例えば、本発明に係る製品の本体、包装、説明書、宣伝物のいずれかに血糖値上昇抑制作用の機能がある旨を表示したものが本発明の範囲に含まれる。例えば、医薬品（医薬部外品を含む）や、特定保健用食品、栄養機能食品、機能性表示食品等の所定機関より効能の表示が認められた機能性食品などのいわゆる健康食品や、飼料等を挙げることができる。いわゆる健康食品においては、「血糖値が気になりはじめた方に」、「（食後の）血糖値が気になる方に」、「血糖値の上昇をおだやかにする」、「糖の吸収をおだやかにする」、「血糖値を抑える」等を表示したものを例示することができる。これらの健康食品は、食事と別に摂取してもよいが、食事の際に摂取することが好ましく、例えば、食事前１時間から食事後１時間の間に摂取することが好ましく、食事前０．５時間から食事後０．５時間の間に摂取することがより好ましく、食事前０．５時間から食事開始時まで或いは食事中に摂取することがさらに好ましい。等を表示したものを例示することができる。 Further, the composition for suppressing the increase in blood glucose level of the present invention contains at least one selected from sweet potato foliage and grapes, cassis and orange, and is distinguished from other products as a product in that it is used for suppressing the increase in blood glucose level. It is not particularly limited as long as it can be used, and for example, it is indicated that any of the main body, packaging, instruction manual, and promotional material of the product according to the present invention has a function of suppressing an increase in blood glucose level. Those are included in the scope of the present invention. For example, so-called health foods such as pharmaceuticals (including non-pharmaceutical products), foods for specified health use, foods with nutritional function, foods with functional claims, and other functional foods whose efficacy has been approved by a prescribed organization, feeds, etc. Can be mentioned. In so-called health foods, "for those who are worried about blood sugar levels", "for those who are worried about blood sugar levels (after meals)", "to moderate the rise in blood sugar levels", "to absorb sugar" It is possible to exemplify those displaying "to be calm", "to suppress the blood sugar level", and the like. These health foods may be taken separately from meals, but are preferably taken at the time of meals, for example, between 1 hour before meals and 1 hour after meals, 0. It is more preferably taken between 5 hours and 0.5 hours after a meal, and even more preferably from 0.5 hours before a meal to the beginning of a meal or during a meal. Etc. can be illustrated as an example.
本発明の組成物の配合量は、配合される製品の種類または剤形、投与または摂取の対象の年齢、性別、体重または状態、投与または摂取の方法、時期または時間などに応じて適宜設定され得る。 The blending amount of the composition of the present invention is appropriately set according to the type or dosage form of the product to be blended, the age, sex, body weight or condition of the subject to be administered or ingested, the method of administration or ingestion, the time or time, and the like. obtain.
本発明の組成物の投与量は、例えば、有効成分として、通常成人１人につき１日１回当たり１０〜２０００ｍｇ、好ましくは１００〜１０００ｍｇ、特に好ましくは３００〜１０００ｍｇである。投与時期は、食前、食間および食後のいずれでもよく、数回に分けて投与してもよい。 The dose of the composition of the present invention is, for example, as an active ingredient, usually 10 to 2000 mg, preferably 100 to 1000 mg, and particularly preferably 300 to 1000 mg once a day per adult. The administration time may be any of pre-meal, inter-meal and post-meal, and may be administered in several divided doses.
本発明の組成物は、経口投与または摂取用の組成物として調製され得る。本発明の組成物は、需要者の嗜好に合わせて、ハードカプセル、ソフトカプセルのようなカプセル剤、錠剤、丸剤などの剤形、または粉末状、顆粒状、飴状などの形状に成形され得る。また、溶液、懸濁液、または乳液のような液状の剤形もしくは形状にも調製され得る。 The compositions of the present invention can be prepared as compositions for oral administration or ingestion. The composition of the present invention can be molded into a capsule such as a hard capsule or a soft capsule, a dosage form such as a tablet or a pill, or a shape such as a powder, a granule, or a candy, according to the taste of a consumer. It can also be prepared in liquid dosage forms or forms such as solutions, suspensions, or emulsions.
本発明の組成物は、医薬品、医薬部外品、特定保健用食品、栄養補助食品、その他の飲食品などとして、あるいはこれらに配合して用いることができる。 The composition of the present invention can be used as or in combination with pharmaceuticals, quasi-drugs, foods for specified health uses, dietary supplements, other foods and drinks, and the like.
本発明の組成物あるいはその配合製品は、剤形もしくは形状または好みに応じて、そのまま摂取しても良いし、水、湯、牛乳、豆乳、茶、ジュースなどに溶かして摂取しても良い。 The composition of the present invention or a compounded product thereof may be ingested as it is, depending on the dosage form, shape or preference, or may be ingested by dissolving it in water, hot water, milk, soymilk, tea, juice or the like.
以下、実施例により本発明をより具体的に説明するが、本発明はこれらの実施例により限定されるものではない。 Hereinafter, the present invention will be described in more detail with reference to Examples, but the present invention is not limited to these Examples.
本発明の経口組成物の形態としては、例えば、錠状、カプセル状、粉末状、顆粒状、液状、粒状、棒状、板状、ブロック状、固形状、丸状、ペースト状、クリーム状、カプレット状、ゲル状、チュアブル状、スティック状等を挙げることができる。これらの中でも、錠状、カプセル状、粉末状、顆粒状、液状の形態が特に好ましい。具体的には、サプリメントや、ペットボトル、缶、瓶等に充填された容器詰飲料や、水（湯）、牛乳、果汁、青汁等に溶解して飲むためのインスタント飲料（粉末飲料）や、食品添加剤を例示することができる。これらは食事の際などに手軽に飲用しやすく、また嗜好性を高めることができるという点で好ましい。 The form of the oral composition of the present invention includes, for example, tablets, capsules, powders, granules, liquids, granules, rods, plates, blocks, solids, rounds, pastes, creams, and caplets. Examples include a shape, a gel shape, a chewable shape, and a stick shape. Among these, tablet-like, capsule-like, powder-like, granular, and liquid forms are particularly preferable. Specifically, supplements, packaged beverages filled in PET bottles, cans, bottles, etc., instant beverages (powdered beverages) for dissolving in water (hot water), milk, fruit juice, green juice, etc. , Food additives can be exemplified. These are preferable in that they are easy to drink at the time of meals and can enhance the palatability.
本発明の経口組成物における甘藷茎葉の含有量としては、その効果の奏する範囲で適宜含有させればよい。 The content of sweet potato foliage in the oral composition of the present invention may be appropriately contained within the range in which the effect is exhibited.
一般的には、本発明の経口組成物が錠状、錠剤状等のサプリメントや医薬品の場合には、本発明の成分が乾燥質量換算で組成物全体の０．０１〜１００質量％含まれていることが好ましく、０．１〜８０質量％含まれていることがより好ましく、１〜６０質量％含まれていることがさらに好ましい。 Generally, when the oral composition of the present invention is a supplement or pharmaceutical product in the form of tablets, tablets, etc., the component of the present invention is contained in an amount of 0.01 to 100% by mass of the entire composition in terms of dry mass. It is preferably contained in an amount of 0.1 to 80% by mass, more preferably 1 to 60% by mass.
本発明の経口組成物が容器詰飲料である場合には、本発明の成分が組成物全体の０．００１〜３０質量％含まれていることが好ましく、０．０１〜２０質量％含まれていることがより好ましく、０．１〜１５質量％含まれていることがさらに好ましい。 When the oral composition of the present invention is a packaged beverage, the component of the present invention is preferably contained in an amount of 0.001 to 30% by mass, preferably 0.01 to 20% by mass, based on the total amount of the composition. It is more preferable that the content is 0.1 to 15% by mass.
また、本発明の経口組成物が青汁やスムージー等のインスタント飲料である場合には、本発明の成分が乾燥質量換算で組成物全体の０．０１〜１００質量％含まれていることが好ましく、０．１〜８０質量％含まれていることがより好ましく、１〜６０質量％含まれていることがさらに好ましい。 When the oral composition of the present invention is an instant beverage such as green juice or smoothie, it is preferable that the component of the present invention is contained in an amount of 0.01 to 100% by mass of the entire composition in terms of dry mass. , 0.1 to 80% by mass is more preferable, and 1 to 60% by mass is further preferable.
本発明の効果をより有効に発揮させるためには、本発明の成分が乾燥質量換算で本発明の経口組成物全体の７０％以上含まれていることが好ましく、８０％以上含まれていることがより好ましく、９０％以上含まれていることがさらに好ましく、１００％であることが特に好ましい。 In order to exert the effect of the present invention more effectively, it is preferable that the component of the present invention is contained in an amount of 70% or more, and 80% or more, of the entire oral composition of the present invention in terms of dry mass. Is more preferable, 90% or more is further preferable, and 100% is particularly preferable.
本発明の経口組成物の摂取量としては特に制限はないが、本発明の効果をより顕著に発揮させる観点から、成人の１日当たり、甘藷茎葉摂取量が乾燥質量換算で、０．０１ｇ／日以上となるように摂取することが好ましく、０．１ｇ／日以上となるように摂取することがより好ましく、１ｇ／日以上となるように摂取することがさらに好ましい。その上限は、例えば、３０ｇ／日であり、好ましくは２０ｇ／日であり、より好ましくは１０ｇ／日である。本発明の経口組成物は、１日の摂取量が前記摂取量となるように、１つの容器に、又は例えば２〜３の複数の容器に分けて、１日分として収容することができる。 The intake of the oral composition of the present invention is not particularly limited, but from the viewpoint of exerting the effect of the present invention more remarkably, the daily intake of sweet potato foliage for adults is 0.01 g / day in terms of dry mass. It is preferable to ingest it so as to be more than 0.1 g / day, more preferably 0.1 g / day or more, and further preferably 1 g / day or more. The upper limit is, for example, 30 g / day, preferably 20 g / day, and more preferably 10 g / day. The oral composition of the present invention can be contained in one container or divided into a plurality of containers, for example, 2 to 3 so that the daily intake becomes the above-mentioned intake.
甘藷茎葉及び他素材（カシス、ブドウ、及びオレンジから選ばれる少なくとも１種）の配合質量比としては、乾燥質量換算で、０．０００１：１〜１００００：１であることが好ましく、０．００１：１〜１０００：１であることがより好ましく、０．０１：１〜１００：１であることがさらに好ましい。 The compounding mass ratio of sweet potato foliage and other materials (at least one selected from cassis, grape, and orange) is preferably 0.0001: 1 to 10000: 1 in terms of dry mass, and 0.001: 0.001: It is more preferably 1 to 1000: 1, and even more preferably 0.01: 1 to 100: 1.
本発明の経口組成物は、必要に応じて、本発明の成分以外の他の成分を添加して、公知の方法によって製造することができる。本発明の成分以外の他の成分としては、例えば、水溶性ビタミン（ビタミンＢ１、Ｂ２、Ｂ３、Ｂ５、Ｂ６、Ｂ１２、Ｂ１３、Ｂ１５、Ｂ１７、ビオチン、コリン、葉酸、イノシトール、ＰＡＢＡ、ビタミンＣ、ビタミンＰ）、油溶性ビタミン（ビタミンＡ、Ｄ、Ｅ、Ｋ）等のビタミン類；カルシウム、マグネシウム、リン、鉄等のミネラル類；タウリン、ニンニク等に含まれる含硫化合物；ヘスペリジン、ケルセチン等のフラバノイド或いはフラボノイド類；コラーゲン等のタンパク質；ペプチド；アミノ酸；動物性油脂；植物性油脂；動物・植物の粉砕物又は抽出物等を挙げることができる。 The oral composition of the present invention can be produced by a known method by adding components other than the components of the present invention, if necessary. Examples of other components other than the components of the present invention include water-soluble vitamins (vitamins B1, B2, B3, B5, B6, B12, B13, B15, B17, biotin, choline, folic acid, inositol, PABA, vitamin C, etc. Vitamins such as vitamin P) and oil-soluble vitamins (vitamins A, D, E, K); minerals such as calcium, magnesium, phosphorus and iron; sulfur-containing compounds contained in taurine, garlic and the like; hesperidin, quercetin and the like Flavanoids or flavonoids; proteins such as collagen; peptides; amino acids; animal fats and oils; vegetable fats and oils; crushed products or extracts of animals and plants.
本発明の経口組成物は、後述する実施例で示されたＧＬＰ−１分泌促進作用を奏することにより、ＧＬＰ−１分泌促進用組成物、糖尿病の予防用組成物、糖尿病の改善用組成物、肥満の予防用組成物、肥満の改善用組成物として優れたものとなり得る。また、後述する実施例で示された血糖値上昇抑制作用を奏することにより、血糖値上昇抑制用組成物、
として優れたものとなり得る。
また、後述する実施例で示された分散性向上の作用を奏することにより、凝集しにくく分散性の高い組成物となり得る。
The oral composition of the present invention exhibits a GLP-1 secretion-promoting action shown in Examples described later, whereby a GLP-1 secretion-promoting composition, a diabetes-preventing composition, a diabetes-improving composition, and the like. It can be excellent as a composition for preventing obesity and a composition for improving obesity. In addition, the composition for suppressing the increase in blood glucose level, which exerts the action of suppressing the increase in blood glucose level shown in Examples described later.
Can be excellent.
In addition, by exerting the action of improving dispersibility shown in Examples described later, a composition that is less likely to aggregate and has high dispersibility can be obtained.
以下、本発明を実施例に基づき説明する。
［試験例１］
試験１：ＧＬＰ−１分泌促進作用及び血糖値上昇抑制作用の評価
Hereinafter, the present invention will be described based on examples.
[Test Example 1]
Test 1: Evaluation of GLP-1 secretagogue action and blood glucose elevation inhibitory action
実施例１において、「甘藷茎葉粉末」とは、「すいおう」の甘藷茎葉を加熱処理後、乾燥処理および粉末化処理を施した茎葉粉末をいう。「カシス抽出物」とは、カシスの実（果皮を含む）を水で抽出したものを乾燥し、粉砕したエキス末をいう。「ブドウ種子エキス」とは、ブドウの種子をエタノールで抽出したものを乾燥し、粉砕したエキス末をいう。 In Example 1, "sweet potato foliage powder" refers to foliage powder obtained by heat-treating sweet potato foliage of "Suiou" and then drying and pulverizing it. "Blackcurrant extract" refers to an extract powder obtained by extracting blackcurrant fruits (including pericarp) with water, drying them, and crushing them. "Grape seed extract" refers to an extract powder obtained by extracting grape seeds with ethanol, drying them, and crushing them.
１．甘藷茎葉含水エタノール抽出物の調製
フラスコに甘藷茎葉粉末１５０ｇを採取した。常温の６０容量％含水エタノール６００ｍＬを加え、スパチュラで粉末を攪拌、および超音波で塊をほぐしながら懸濁し、常温にて、スターラーで２時間攪拌した。フラスコ内容物を吸引ろ過し、ろ液を回収した。ろ紙上の残渣をフラスコに回収し、新しい６０容量％含水エタノール６００ｍＬに再度懸濁した後、常温にて、スターラーで２時間攪拌した。フラスコ内容物を吸引ろ過し、ろ液を回収した。ろ過１回目と２回目のろ液をあわせて減圧濃縮（水温４０℃）した後、凍結乾燥し、粉末を得た（以下、単に「含水エタノール抽出物」または「甘藷茎葉含水エタノール抽出物」ともいう）。
1. 1. Preparation of sweet potato foliage hydrous ethanol extract 150 g of sweet potato foliage powder was collected in a flask. 600 mL of 60% by volume hydrous ethanol at room temperature was added, the powder was stirred with a spatula, and the lumps were suspended while being loosened by ultrasonic waves, and the mixture was stirred at room temperature for 2 hours with a stirrer. The contents of the flask were suction filtered and the filtrate was collected. The residue on the filter paper was collected in a flask, suspended again in 600 mL of fresh 60% by volume hydrous ethanol, and then stirred at room temperature for 2 hours with a stirrer. The contents of the flask were suction filtered and the filtrate was collected. The first and second filtrates of the filtration were combined and concentrated under reduced pressure (water temperature 40 ° C.), and then freeze-dried to obtain a powder (hereinafter, also referred to simply as "hydrous ethanol extract" or "sweet potato foliage hydrous ethanol extract". Say).
２．被験試料の調製
カルボキシメチルセルロースナトリウム（富士フイルム和光純薬社。以下、「ＣＭＣ」ともいう）を０．５％（ｗ／ｖ）となるように純水に溶解した。下記表に示す濃度になるように、上記被験物質を０．５％（ｗ／ｖ）ＣＭＣ水溶液に懸濁して、被験試料とした。また、０．５％（ｗ／ｖ）ＣＭＣ水溶液をコントロール試料とした。
2. 2. Preparation of test sample Sodium carboxymethyl cellulose (Fujifilm Wako Pure Chemical Industries, Ltd., hereinafter also referred to as "CMC") was dissolved in pure water to a concentration of 0.5% (w / v). The above test substance was suspended in a 0.5% (w / v) CMC aqueous solution to prepare a test sample so as to have the concentration shown in the table below. Further, a 0.5% (w / v) CMC aqueous solution was used as a control sample.
３．グルコース溶液の調製
グルコース（ナカライテスク社）を２００ｍｇ／ｍＬの濃度となるように純水に溶解した。
3. 3. Preparation of Glucose Solution Glucose (Nacalai Tesque) was dissolved in pure water to a concentration of 200 mg / mL.
４．ＤＰＰ−４阻害溶液の調製
エチレンジアミン四酢酸二ナトリウム（ＥＤＴＡ−２Ｎａ；同仁化学研究所社）及びＤＰＰ−４阻害薬（アプロチニン（生化学用；富士フイルム和光純薬社）及びＤｉｐｒｏｔｉｎ−Ａ（ペプチド研究所社））を含む混合液を、ＤＰＰ−４阻害溶液として調製した。具体的には、生理食塩液（大塚製薬工場社）を溶媒として、血液中最終濃度が、ＥＤＴＡ−２Ｎａ １ｍｇ／ｍＬ、アプロチニン ５００ＫＩＵ／ｍＬ、及びＤｉｐｒｏｔｉｎ−Ａ ０．１ｍＭとなるように、５０倍濃度の混合液を作製した。使用時まで氷中にて保存した。
4. Preparation of DPP-4 Inhibitor Solution Ethylenediaminetetraacetic acid disodium (EDTA-2Na; Dojin Chemical Research Institute), DPP-4 inhibitor (Aprotinin (for biochemistry; Fujifilm Wako Junyakusha)) and Diprotin-A (peptide research) A mixed solution containing)) was prepared as a DPP-4 inhibitory solution. Specifically, using physiological saline (Otsuka Pharmaceutical Factory, Inc.) as a solvent, the final concentration in blood is 50 times so that the final concentration in blood is EDTA-2Na 1 mg / mL, aprotinin 500 KIU / mL, and Diprotin-A 0.1 mM. A mixed solution having a concentration was prepared. Stored in ice until use.
ＳＤ系雄性ラットを試験前日より１６時間以上絶食させた。その後、各ラットは、試験当日に被験物質投与前の血糖値および体重値がほぼ均一となるように群分けした。各ラットに対して、試験当日の体重値に基づき、各被験試料を、１０ｍＬ／ｋｇにてゾンデを用いて強制的に経口投与した。被験物質投与４０分後に、グルコース溶液を１０ｍＬ／ｋｇにてゾンデを用いて強制的に経口投与した。 Male SD rats were fasted for 16 hours or more from the day before the test. Then, each rat was grouped so that the blood glucose level and the body weight level before administration of the test substance were almost uniform on the day of the test. Each rat was forcibly orally administered at 10 mL / kg using a sonde based on the weight value on the day of the test. Forty minutes after administration of the test substance, the glucose solution was forcibly orally administered at 10 mL / kg using a sonde.
グルコース溶液投与２０分後にイソフルラン麻酔下において開腹し、門脈採血を行った。門脈採血は、２．５ｍＬシリンジ及び２３Ｇ１／２針を使用し、一定量（１ｍＬ）の血液を採取することにより実施した。活性型ＧＬＰ−１を不活性型ＧＬＰ−１に変換する酵素であるＤＰＰ−４の作用を抑制するために、採血直前にＤＰＰ−４阻害溶液をシリンジに２０μL入れた。 Twenty minutes after the administration of the glucose solution, the abdomen was opened under isoflurane anesthesia, and portal vein blood was collected. Portal vein blood sampling was performed by collecting a fixed amount (1 mL) of blood using a 2.5 mL syringe and a 23 G1 / 2 needle. In order to suppress the action of DPP-4, which is an enzyme that converts active GLP-1 into inactive GLP-1, 20 μL of a DPP-4 inhibitory solution was placed in a syringe immediately before blood collection.
得られた血液を、１，０００ｇ、１０分、４℃の条件下で遠心し、血漿を採取した。得られた血漿は測定まで−８０℃下にて冷凍保存した。 The obtained blood was centrifuged at 1,000 g for 10 minutes at 4 ° C., and plasma was collected. The obtained plasma was stored frozen at −80 ° C. until measurement.
市販のキット（レビスＧＬＰ−１（Ａｃｔｉｖｅ）；富士フイルムワコーシバヤギ社）を用いて、血漿中の活性型ＧＬＰ−１濃度を測定した。得られた血漿中の活性型ＧＬＰ−１濃度について、各群で平均値を算出した。 A commercially available kit (Levis GLP-1 (Active); FUJIFILM Wakoshibayagi Co., Ltd.) was used to measure the concentration of active GLP-1 in plasma. The average value of the active GLP-1 concentration in the obtained plasma was calculated for each group.
また、群分け時、グルコース投与０分後、グルコース投与２０分後に２６Ｇ針を用いてラット尾静脈より採血し、グルテストセンサーを装着した小型血糖値測定器（グルテストエースＲ；三和化学研究所社）にて血糖値を測定した。 In addition, at the time of grouping, 0 minutes after glucose administration and 20 minutes after glucose administration, blood was collected from the rat tail vein using a 26G needle, and a small blood glucose meter equipped with a glutest sensor (Glutest Ace R; Sanwa Kagaku Kenkyusho). The blood glucose level was measured at the company).
５．結果
各被験試料群の血漿中活性型ＧＬＰ−１濃度の測定結果を表２及び図１に示す。驚くべきことに、甘藷茎葉含水エタノール抽出物と共にカシス抽出物及びブドウ種子エキスを用いた混合物の群（実施例１）は、甘藷茎葉含水エタノール抽出物のみからなる群（比較例１）に比べて、約１．３倍の活性型ＧＬＰ−１値を示した。これらの結果から、甘藷茎葉と共にブドウ及びカシスを用いた混合物は、格別顕著な活性型ＧＬＰ−１分泌促進作用を示すことが示唆される。
5. Results The measurement results of the plasma active GLP-1 concentration of each test sample group are shown in Table 2 and FIG. Surprisingly, the group of the mixture using the cassis extract and the grape seed extract together with the sweet potato foliage-containing ethanol extract (Example 1) was compared with the group consisting only of the sweet potato foliage-containing ethanol extract (Comparative Example 1). , About 1.3 times the active GLP-1 value. From these results, it is suggested that the mixture using grapes and cassis together with sweet potato foliage shows a particularly remarkable active GLP-1 secretion promoting action.
各被験試料群のグルコース投与２０分後の血糖値の測定結果を表３及び図２に示す。驚くべきことに、甘藷茎葉含水エタノール抽出物と共にカシス抽出物及びブドウ種子エキスを用いた混合物の群（実施例１）は、甘藷茎葉含水エタノール抽出物のみからなる群（比較例１）の、約８１％の血糖値を示した。これらの結果から、甘藷茎葉と共にブドウ及びカシスを用いた混合物は、格別顕著な血糖値上昇抑制作用を示すことが示唆される。 The measurement results of the blood glucose level 20 minutes after glucose administration of each test sample group are shown in Table 3 and FIG. Surprisingly, the group of the mixture using the cassis extract and the grape seed extract together with the sweet potato foliage-containing ethanol extract (Example 1) is about the group consisting of only the sweet potato foliage-containing ethanol extract (Comparative Example 1). The blood glucose level was 81%. From these results, it is suggested that the mixture using grapes and cassis together with sweet potato foliage shows a particularly remarkable inhibitory effect on blood glucose elevation.
［試験例２］
（粒度試験）
（サンプルの調製）
甘藷茎葉としては、「すいおう」の甘藷茎葉を加熱処理後、乾燥処理および粉末化処理を施した甘藷茎葉粉末を用いた。
ブドウとしては、ブドウの種子をエタノールで抽出したものを乾燥し、粉砕したエキス末を用いた。
カシスとしては、カシスの実（果皮を含む）を水で抽出したものを乾燥し、粉砕したエキス末を用いた。
オレンジとしては、オレンジの果実（果皮を含む）をアルカリ溶液で抽出したものを乾燥し、粉砕したエキス末を用いた。
[Test Example 2]
(Particle size test)
(Sample preparation)
As the sweet potato foliage, sweet potato foliage powder obtained by heat-treating the sweet potato foliage of "Suiou" and then drying and pulverizing the sweet potato foliage was used.
As the grapes, the grape seeds extracted with ethanol were dried, and the crushed extract powder was used.
As the cassis, the extract powder obtained by extracting the cassis fruit (including the peel) with water, drying it, and crushing it was used.
As the orange, an orange fruit (including the peel) extracted with an alkaline solution, dried, and crushed extract powder was used.
各サンプルを下記表４（単位：ｇ）に示す分量でよく混合した。そのうちの８ｇを使って混合物の粒度を測定した。 Each sample was mixed well in the amounts shown in Table 4 (unit: g) below. 8 g of it was used to measure the particle size of the mixture.
具体的には、ミクロ型電磁振動ふるい器Ｍ−２型（筒井理化学器械（株）製）を用いて粒度を測定した。測定条件は、各サンプル８ｇにつき、振動度の目盛りを５に合わせて、振動時間を５分とした。使用した篩は、目開きが１５０、１０６μｍの２種類で、受け器の上に、下から目開きの小さい順に大きなものを重ねて使用した。５分間の振動後、各篩及び受け器に残った粉末を回収し、当該粉末の重量を測定した。
その結果を表５及び図３に示す。
Specifically, the particle size was measured using a micro-type electromagnetic vibration sieve M-2 type (manufactured by Tsutsui Rikagaku Kikai Co., Ltd.). As for the measurement conditions, the vibration degree scale was set to 5 and the vibration time was set to 5 minutes for each 8 g of the sample. There were two types of sieves used, with openings of 150 and 106 μm, and the sieves used were placed on the receiver in ascending order of opening from the bottom. After shaking for 5 minutes, the powder remaining on each sieve and receiver was collected and the weight of the powder was measured.
The results are shown in Table 5 and FIG.
表５及び図３に示すように、甘藷若葉末と共にブドウ種子抽出物、カシス抽出物又はオレンジ抽出物を用いた混合物（実施例２〜４）における１５０μｍ以下の粒度の小さい粉末の回収量は、甘藷茎葉末単独の場合（比較例２）よりも増加しており、ダマの形成（凝集）が抑制されたことがわかる。また、実施例２〜４の粉末回収量は、甘藷茎葉末、ブドウ種子抽出物、カシス抽出物、オレンジ抽出物それぞれ単独の場合（比較例２〜５）よりも増加しており、組み合せによる相乗的な凝集抑制効果がみられた。さらに、実施例５に示すように、甘藷茎葉末に、ブドウ種子抽出物及びカシス抽出物を加えることにより、その凝集抑制効果が大きくなった。さらに、実施例６〜８に示すように、甘藷若葉末に、ブドウ種子抽出物、カシス抽出物及びオレンジ抽出物を加えることにより、その凝集抑制効果はさらに大きくなり、顕著なものとなった。 As shown in Table 5 and FIG. 3, the amount of small powder having a particle size of 150 μm or less in the mixture (Examples 2 to 4) using the grape seed extract, the cassis extract or the orange extract together with the young sweet potato leaf powder was determined. It was increased as compared with the case of sweet potato foliage powder alone (Comparative Example 2), and it can be seen that the formation (aggregation) of lumps was suppressed. In addition, the amount of powder recovered in Examples 2 to 4 was higher than that in the case of each of the sweet potato foliage powder, grape seed extract, cassis extract, and orange extract alone (Comparative Examples 2 to 5), and synergistically by the combination. The effect of suppressing aggregation was observed. Further, as shown in Example 5, by adding the grape seed extract and the blackcurrant extract to the end of the sweet potato foliage, the aggregation inhibitory effect was enhanced. Further, as shown in Examples 6 to 8, by adding the grape seed extract, the blackcurrant extract and the orange extract to the young sweet potato leaf powder, the aggregation suppressing effect was further increased and became remarkable.
以下に本発明の種々の態様の例を挙げるが、本発明の技術的範囲はこれらに限定されない。 Examples of various aspects of the present invention are given below, but the technical scope of the present invention is not limited thereto.
［配合例］
下記表６の配合にて、甘藷茎葉と、ブドウ、カシス及びオレンジから選ばれる少なくとも１種をそれぞれ配合して型流動層造粒機に投入し、数分間気流で混合し、これに、水６０Ｌを１分間に２０００ｍＬ噴霧することにより造粒を行った。つづいて、得られた造粒物を３０メッシュの篩いにて篩別し顆粒を製造した。得られた飲食用組成物を摂取したところ、ＧＬＰ−１分泌促進効果、血糖値上昇抑制効果が高く、また、分散性の高いものであった。
[Formulation example]
In the formulation shown in Table 6 below, sweet potato foliage and at least one selected from grapes, blackcurrants and oranges are blended and put into a mold fluidized bed granulator, mixed with an air flow for several minutes, and 60 L of water is added to this. Was granulated by spraying 2000 mL per minute. Subsequently, the obtained granules were sieved with a 30-mesh sieve to produce granules. When the obtained food and drink composition was ingested, it was found to have a high GLP-1 secretion promoting effect, a high blood glucose level elevation suppressing effect, and a high dispersibility.
＜製造例７〜製造例１２＞
下記表７の配合にて、甘藷茎葉と、ブドウ、カシス及びオレンジから選ばれる少なくとも１種をそれぞれ配合して、均一になるように混合することによって粉末飲料を製造した。得られた飲食用組成物３ｇを１５０ｍＬの水と混合し、飲用したところ、ＧＬＰ−１分泌促進効果、血糖値上昇抑制効果が高く、また、分散性の高く、優れた組成物を得られた。
<Manufacturing Example 7 to 12>
A powdered beverage was produced by blending sweet potato foliage and at least one selected from grapes, blackcurrants and oranges in the formulation shown in Table 7 below and mixing them uniformly. When 3 g of the obtained edible composition was mixed with 150 mL of water and drunk, an excellent composition having a high GLP-1 secretion promoting effect and a high blood glucose level increase suppressing effect, and having high dispersibility was obtained. ..
＜製造例１３〜製造例１８＞
下記表８の配合にて、甘藷茎葉と、ブドウ、カシス及びオレンジから選ばれる少なくとも１種をそれぞれ配合して、均一になるように混合し、被膜で被包することによってソフトカプセルを製造した（１粒あたり３００ｍｇ）。得られた飲食用組成物を摂取したところ、ＧＬＰ−１分泌促進効果、血糖値上昇抑制効果が高く、また、分散性の高いものであった。
<Manufacturing Example 13 to 18>
In the formulation shown in Table 8 below, sweet potato foliage and at least one selected from grapes, blackcurrants and oranges were blended, mixed so as to be uniform, and encapsulated with a coating to produce soft capsules (1). 300 mg per grain). When the obtained food and drink composition was ingested, it was found to have a high GLP-1 secretion promoting effect, a high blood glucose level elevation suppressing effect, and a high dispersibility.
＜製造例１９〜製造例２４＞
下記表９の配合にて、甘藷茎葉と、ブドウ、カシス及びオレンジから選ばれる少なくとも１種をそれぞれ配合して、均一になるように混合し、均一になるように混合し、被膜に充填することによってハードカプセルを製造した（１粒あたり３５０ｍｇ）。得られた飲食用組成物を摂取したところ、ＧＬＰ−１分泌促進効果、血糖値上昇抑制効果が高く、また、分散性の高いものであった。
<Manufacturing Example 19 to 24>
In the formulation shown in Table 9 below, the sweet potato foliage and at least one selected from grape, cassis and orange are blended, mixed so as to be uniform, mixed so as to be uniform, and filled in the coating film. Hard capsules were produced by (350 mg per capsule). When the obtained food and drink composition was ingested, it was found to have a high GLP-1 secretion promoting effect, a high blood glucose level elevation suppressing effect, and a high dispersibility.
＜製造例２５〜製造例３０＞
下記表１０の配合にて、甘藷茎葉と、ブドウ、カシス及びオレンジから選ばれる少なくとも１種をそれぞれ配合して、均一になるように混合することによって液体飲料を製造した。得られた飲食用組成物を摂取したところ、ＧＬＰ−１分泌促進効果、血糖値上昇抑制効果が高く、また、分散性の高いものであった。
<Production Example 25 to Production Example 30>
A liquid beverage was produced by blending sweet potato foliage and at least one selected from grapes, blackcurrants and oranges in the formulation shown in Table 10 below and mixing them uniformly. When the obtained food and drink composition was ingested, it was found to have a high GLP-1 secretion promoting effect, a high blood glucose level elevation suppressing effect, and a high dispersibility.
＜製造例３１〜製造例３６＞
下記表１１の配合にて、甘藷茎葉と、ブドウ、カシス及びオレンジから選ばれる少なくとも１種をそれぞれ配合して、均一になるように混合した後、打錠装置を用いて成形することによって錠剤を製造した（１粒あたり２５０ｍｇ）。得られた飲食用組成物を摂取したところ、ＧＬＰ−１分泌促進効果、血糖値上昇抑制効果が高く、また、分散性の高いものであった。
<Manufacturing Examples 31 to 36>
In the formulation shown in Table 11 below, sweet potato foliage and at least one selected from grape, cassis and orange are each blended, mixed so as to be uniform, and then molded using a tableting device to obtain tablets. Manufactured (250 mg per grain). When the obtained food and drink composition was ingested, it was found to have a high GLP-1 secretion promoting effect, a high blood glucose level elevation suppressing effect, and a high dispersibility.
本発明の経口組成物は、いわゆる健康食品等として用いることができることから、産業上有用である。 Since the oral composition of the present invention can be used as a so-called health food or the like, it is industrially useful.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019035917A JP7505728B2 (en) | 2019-02-28 | 2019-02-28 | Oral Compositions |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019035917A JP7505728B2 (en) | 2019-02-28 | 2019-02-28 | Oral Compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020138936A true JP2020138936A (en) | 2020-09-03 |
| JP7505728B2 JP7505728B2 (en) | 2024-06-25 |
Family
ID=72279840
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019035917A Active JP7505728B2 (en) | 2019-02-28 | 2019-02-28 | Oral Compositions |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP7505728B2 (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104247919A (en) * | 2013-06-30 | 2014-12-31 | 青岛蓝色科技信息管理有限公司 | Health preserving porridge for people with blood stasis constitution, and preparation method thereof |
| CN105901695A (en) * | 2016-04-15 | 2016-08-31 | 杨胜 | Body building and slimming nutritional granule |
| CN105901696A (en) * | 2016-04-15 | 2016-08-31 | 杨胜 | Detoxification and beautifying nutritional granule |
| CN106754025A (en) * | 2016-12-20 | 2017-05-31 | 潜山县天柱山糯米封缸酒业有限公司 | A kind of aid digestion jar-sealed wine and its brewing method |
-
2019
- 2019-02-28 JP JP2019035917A patent/JP7505728B2/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104247919A (en) * | 2013-06-30 | 2014-12-31 | 青岛蓝色科技信息管理有限公司 | Health preserving porridge for people with blood stasis constitution, and preparation method thereof |
| CN105901695A (en) * | 2016-04-15 | 2016-08-31 | 杨胜 | Body building and slimming nutritional granule |
| CN105901696A (en) * | 2016-04-15 | 2016-08-31 | 杨胜 | Detoxification and beautifying nutritional granule |
| CN106754025A (en) * | 2016-12-20 | 2017-05-31 | 潜山县天柱山糯米封缸酒业有限公司 | A kind of aid digestion jar-sealed wine and its brewing method |
Also Published As
| Publication number | Publication date |
|---|---|
| JP7505728B2 (en) | 2024-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010209051A (en) | Fat absorption inhibitor | |
| JP5685752B2 (en) | Blood flow promoting agent | |
| JP2006045212A (en) | Oral composition containing specific quinic acid derivative | |
| JP2022031912A (en) | Oral composition | |
| JP2008120772A (en) | Obesity inhibitor and edible composition | |
| JP2008163002A (en) | Obesity-preventing and improving agent | |
| JP6619153B2 (en) | Green juice | |
| JP2014141438A (en) | Formulation, food and drink containing novel madeira vine product | |
| JP5248023B2 (en) | Calcium absorption promoting composition | |
| JP2005170836A (en) | Marine alga extract and lipase inhibitor containing the same | |
| JP7505728B2 (en) | Oral Compositions | |
| JP2008163003A (en) | Fat absorption inhibitor | |
| JP6273440B2 (en) | GLP-1 production promoter, DPPIV inhibitor and glucose absorption inhibitor | |
| JP7117763B2 (en) | oral composition | |
| JP7156683B2 (en) | oral composition | |
| JP2003189818A (en) | Functional food containing powdery sea-squirt | |
| KR101018404B1 (en) | Compositions for reducing cholesterol comprising extracts of Vaccinium oldhami Miquel leaf as an active ingredient | |
| JP2014505071A (en) | Plant extract preparation process | |
| JP7090864B2 (en) | Composition | |
| JP4768105B2 (en) | Oral composition | |
| JP6094985B2 (en) | A novel application of hot water extract of intermediate layer with removal of rough stems in bamboo to promote bone length growth | |
| RU2807722C1 (en) | Food product required in case of lack of breast milk | |
| JP7401082B2 (en) | Oral composition | |
| JP2018009038A (en) | Oral composition | |
| JP7203394B1 (en) | oral composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190304 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220224 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20221226 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230105 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230306 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230502 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230724 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230921 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231211 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240507 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240606 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7505728 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |